Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 8, Issue SUPPL., 2009, Pages 17-22

  Shah, Usman ^a   Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Douillard regimen; Drug holiday; Leucovorin; Panitumumab

Indexed keywords

EID: 84860628302     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70552-7     Document Type: Review

References (30)

1. American Cancer Society. Cancer Facts and Figures 2007. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf.Accessed: June 20, 2008.
2. Saif M, Kim R, Chu E. Cytotoxic chemotherapy for metastatic colorectal cancer. In: Saltz LB, ed. Colorectal Cancer: Evidence-Based Chemotherapy Strategies. Totowa, NJ: Humana Press; 2007; 69-70.
3. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol2004; 22:3766-75.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectd cancer. Irinotecan Study Group. N EnglJMed 2000; 343:905-14.
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7. (Pubitemid 30162806)
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000; 18:2938-47. (Pubitemid 30644117)
7. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004; 22:23-30. (Pubitemid 41095110)
8. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-8.
9. Meta-analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol1998; 16:3537-41.
10. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004; 22:229-37. (Pubitemid 41095086)
11. Colucci G, Gebbia V, Paoletti G, et al. Phase 111 randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol2005; 23:4866-75. (Pubitemid 46223991)
12. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol2005; 23:9441-2.
13. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004; 22: 1209-14. (Pubitemid 41079833)
14. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase 111 trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94:798-805.
15. Falcone A, Ricci S, Brunetti I, et al. Phase 111 trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007; 25:1670-6. (Pubitemid 46797946)
16. Hunvitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N EnglJMed 2004; 350:2335-42. (Pubitemid 38702844)
17. Giantonio BJ, Catalan0 PJ, Meropol NJ, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at: the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Florida. Abstract 169a.
18. Hochster HS, Hart LL, Ramanathan RK, et al. Childs Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumah as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol2006; 24( 18 suppl): 148s (Abstract 3510).
19. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstline treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol2007; 25:4779-86. (Pubitemid 350086481)
20. Cunningham D, Humbler Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 35 1:337-45. (Pubitemid 38944402)
21. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase 111 study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007; 25( 18 suppl):164s (Abstract 4000).
22. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximah plus 5-FU/ FNoxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase I1 study. J Clin Oncol2007 25( 18 suppl): 172s (Abstract 4035).
23. Bokemeyer C, Makhson A, Bondarenko I, et al. Cetuximab plus 5FU/FNoxaliplatin (FOLFOX4) in the first line treatment of metastatic colorectal cancer (mCRC): a large-scale phase I1 study, OPUS. Eur J Cancer 2007; 5(suppl):236.
24. Hecht JR, Chidiac T, Scroggin C, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumah (bev) +/- panitumumab (pmab) for first line treatment of metastatic colon cancer from a ran- aomia, controlled trial (PACCE). Presented at: the American Society of Clinical Oocology 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida, Abstract 273.
25. Hecht JH, Chidiac T, Seroggn C, tai. Interim results from PACCE: irinotecan/bevacizumab -i-I- panitumumab as first line treatment for n,etastaric colorecral cancer. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando Florida. Abstract 279.
26. Salra LB. Lena HJ, Klndler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinocecan compared with cetuximab and bevacizumab alone in irinotecanreFracrory colorectal cancer: the BOND-2 smdyJClin Oneol2007; 25:4557-6L
27. Fog C, Marsrel .1. Scheithmaer W er a!. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplarin..based rherap The EPIC trial. J CIin Osarol 2007; 25(18 suppl): 164s (Abstract 4003).
28. Koopman M, Anronini NP, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorecral cancer (CAIRO): a phase Ill randomised controlled trial. Lancet 2007; 370:135-42. (Pubitemid 47042893)
29. Seymour MT. Maughan TS, Ledermann JA, et a!. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorecral cancer (MRC FOCUS): a randomised controlled trial, Lancet 2007; 370:143-52 (Pubitemid 47042894)
30. Schmoll HJ, Sargent 0. Sing)e agent fluorouracil for first-line treatment of advanced colorecral cancer a standard? Lancet J 2007; 370:105-7. (Pubitemid 47042877)